Accelr8 and Becton Dickinson Conclude Technical Development Project
September 25 2009 - 1:14PM
Business Wire
Accelr8 Technology Corporation (NYSE Amex: AXK) announced
today that it has concluded a technical development project with
Becton, Dickinson and Company (“BD”) (NYSE: BDX). Accelr8’s
technology met formal testing requirements for identification of a
subset of relevant species of bacteria. However, BD advised the
Company that it has decided to decline an associated exclusive
technology license option. At any time, BD has numerous new product
opportunities, and prioritizes projects on the basis of decision
criteria that are not limited to technical factors.
According to David Howson, Accelr8’s president, “We’re
disappointed by BD’s decision not to exercise its exclusive option.
Nevertheless, we made substantial advances and gained strong
supporting technical evidence in the project, including integrated
testing using patient specimens. We will continue discussions with
other prospective collaborators. The BACcel™ rapid diagnostic
system remains the only technology yet supported by published data
to have the capability to provide same-day analysis of all
significant highly drug-resistant bacteria and their particular
resistance mechanisms.”
About Accelr8
Accelr8 Technology Corporation (www.accelr8.com) is a developer
of innovative materials and instrumentation for advanced
applications in medical instrumentation and biosciences basic
research. Accelr8 is developing a rapid clinical pathogen
diagnostic platform, the BACcel™, based on its wholly-owned
intellectual property. In addition, Accelr8 licenses certain of its
proprietary technology for use in applications outside of Accelr8’s
own products.
Certain statements in this news release may be “forward-looking
statements” within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Statements regarding future prospects and
developments are based upon current expectations and involve
certain risks and uncertainties that could cause actual results and
developments to differ materially from the forward-looking
statement, including those detailed in the company's filings with
the Securities and Exchange Commission. Accelr8 does not undertake
an obligation to publicly update or revise any forward-looking
statements, whether as a result of new information or future
events.
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Accelr8 (AMEX:AXK)
Historical Stock Chart
From Jul 2023 to Jul 2024